



PHARMERIT

AN OPEN HEALTH COMPANY



OPENVIE

VALUE · INFORMATICS · EVIDENCE

VIRTUAL ISPOR EUROPE 2020

16-19 NOVEMBER 2020

ON DEMAND SESSIONS

TITLE	PRESENTERS	SESSION
Cost-effectiveness Modelling of Complex Pathways	Elisabeth Fenwick	On Demand
Reducing Structural Uncertainty in Survival Extrapolations: Bayesian Model Averaging and External Data	Sven Klijn, Katharina Nickel	On Demand

PHARMERIT POSTERS

TITLE	AUTHOR(S)	SESSION
Treatment Sequencing in Modeling the Economic Benefits of Psoriasis Therapy- IMPACT of Key Assumptions	Gijs van de Wetering, Tim Ignacio	PBI9
Efficacy & Safety in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma - a Systematic Literature Review Update	Carla Kraan, Lisette Nientker, Jelle Spoorendonk	PCN14
Overall Complete Remission Rate (OCRR) and Complete Remission Rate (CR) Of Standard of Care (SoC) In Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Meta-Analysis	Olaf Schoeman, Lisette Nientker	PCN36
Real-World Effectiveness in Previously Untreated, Advanced/ Metastatic Renal Cell Carcinoma - a Systematic Literature Review Update	Anne Marie Trip, Jelle Spoorendonk	PCN37
Cost-Effectiveness Models and Resource Use/Cost Inputs for Untreated Advanced/Metastatic Renal Cell Carcinoma- A Systematic Literature Review	Allysen Kaminski, Cathelijne Alleman	PCN80
Global Incidence, Prevalence, and Survival in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Systematic Literature Review (SLR)	Jelle Spoorendonk, Dhwani Shah	PCN183
Clinical Characteristics and Minimal Residual Disease (MRD) Testing Patterns in NEWLY Diagnosed Patients with B-CELL Precursor ACUTE Lymphoblastic Leukemia (ALL) from Italy: A Retrospective	Walter Bouwmeester, Katharina Verleger	PCN220
Reported Utilities for Patients with Previously Untreated Advanced/ Metastatic Renal Cell Carcinoma - A Systematic Literature Review	Omer Zaidi, Cathelijne Alleman	PCN301
Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)	Venetia Qendri, Esra Cakar, Sven L. Klijn	PDG5
Existing Health Economic Evaluations of Inflammatory Bowel Disease Show Important Methodological Limitations: A Targeted Literature Review	Lisanne Verburg, Nicholas Durno	PGI13

PHARMERIT POSTERS

TITLE	AUTHOR(S)	SESSION
Where Are WE Headed with Digital Therapeutics? a Systematic Review of the Evidence	Emanuele Arcà, Kristina Hartl, Amrita Ostawal	PMU57
Identifying Appropriate PROXY Diseases for Estimating LONG-TERM Survival and IMPACT on Health-Related Quality of Life of Patients with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D)	Martina Bianco, Poojee Sudhapalli, Claire Simons, Craig Bennison	PRO10
Estimating the LONG-TERM Effects of Therapy for Patients with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) Using Individual Participant DATA	Claire Simons, Poojee Sudhapalli, Craig Bennison	PRO11
Synthesizing Evidence on Progression-Free Survival and Assessing The Feasibility of Network Meta-Analyses in Previously Untreated Advanced/Metastatic Renal Cell Carcinoma Therapies	Manon Grevinga, Nora Szabo, Sonja Kroep	PUK1
The Impact of Clinical Heterogeneity on Conducting Network Meta-Analyses for Overall Survival in Previously Untreated Intermediate- or Poor-Risk Advanced/Metastatic Renal Cell Carcinoma Therapies	Nora Szabo, Manon Grevinga, Sonja Kroep	PUK2
Synthesizing Evidence on Overall Survival and Assessing the Feasibility of Network Meta-Analyses in Previously Untreated Advanced/ Metastatic Renal Cell Carcinoma Therapies	Manon Grevinga, Nora Szabo, Sonja Kroep	PUK3
The Impact of Clinical Heterogeneity on Conducting Network Meta-Analyses for Progression-Free Survival of Previously Untreated Intermediate- or Poor-Risk Advanced/Metastatic Renal Cell Carcinoma Therapies	Nora Szabo, Manon Grevinga, Sonja Kroep	PUK4
Systematic Identification of Potential Treatment Effect Modifiers in First Line Advanced Renal Cell Carcinoma	Manon Grevinga, Sonja Kroep	PUK5

OPEN VIE POSTERS

TITLE	AUTHOR(S)	SESSION
Analysis of Hospital Episode Statistics Data to Demonstrate the Secondary Care Treatment Pathway and Outcomes of Patients with Cutaneous T-Cell Lymphoma in England	Fiona Glen, Dave Heato	PCN333
End of Life Secondary Care Resource Use and Costs in Mycosis Fungoides and Sézary Syndrome- An Analysis of Hospital Episode Statistics	Fiona Glen, Dave Heaton	PCN344

See how we are an integrated, global team of research and communication experts working together to improve the lives of patients worldwide at pharmerit.com/openhealth.

Modeling & Meta-Analysis • Patient-Centered Outcomes •
Real-World Evidence • Strategic Market Access

www.pharmerit.com

© Copyright 2020 Pharmerit – an OPEN Health Company | All Rights Reserved.